Browse the evidence

GLP-1 receptor agonist therapy induces predictable reductions in fat-free mass (approximately 30-40% of total weight loss) due to sustained negative energy balance, not direct catabolic effects.

Expect that about a third of your weight loss on GLP-1s will be muscle/fluid, not just fat. This is normal physiology, not a side effect. To mitigate this, prioritize protein intake and resistance training, especially if you have low testosterone.

Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic cardiovascular, metabolic, and renal benefits in cardiometabolic syndrome (CMS) patients, though implementation is hindered by hypotension risks and cost.

If you have cardiometabolic syndrome, current guidelines suggest combining an ARNI (like sacubitril/valsartan) with an SGLT2 inhibitor (like empagliflozin or dapagliflozin) for the best heart, kidney, and metabolic protection. Start with low doses and increase slowly to avoid dizziness or low blood pressure. Monitor your kidney function and electrolytes regularly. Discuss insurance coverage with your provider, as these drugs can be expensive but are cost-effective long-term by preventing hospitalizations.

Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.

If you have kidney disease and heart issues, ask your doctor about finerenone. It protects your kidneys and heart with a lower risk of dangerous potassium levels compared to older drugs. It is taken once daily.

Genetically proxied GIPR agonist reduces the risk of 14 cardiometabolic diseases, including obesity, hypertension, and coronary heart disease, with effects on angina and myocardial infarction partially mediated by the inflammatory biomarker Flt3L.

Genetic evidence supports that activating the GIP receptor reduces the risk of major cardiometabolic diseases, including obesity, hypertension, and heart conditions. This benefit is partly achieved by lowering levels of the inflammatory protein Flt3L, which is linked to angina and heart attacks. This suggests GIP-targeting therapies could offer broader heart health benefits beyond blood sugar control.

Higher body mass index (BMI) causes structural remodeling of the right ventricle, specifically increasing end-diastolic and end-systolic volumes, independent of left ventricular measures.

Maintaining a healthy BMI is crucial for protecting the structure of your right ventricle. This study shows that higher body weight is causally linked to larger heart volumes, which can lead to dysfunction over time. Weight management strategies, including diet and exercise, can help prevent this structural remodeling.

Standard diagnostic thresholds for natriuretic peptides (BNP/NT-proBNP) are less sensitive in individuals with obesity, potentially missing cases of HFpEF, necessitating adjusted cutoffs or alternative screening scores.

If you have obesity, standard blood tests for heart failure (BNP/NT-proBNP) might not be sensitive enough to detect early problems. Ensure your doctor interprets these results in the context of your weight or uses specialized scoring systems (like the HFpEF-ABA score) that account for obesity.

Over an 8-year period, middle-aged adults of African origin across diverse geographic and socioeconomic settings experienced significant increases in the prevalence and incidence of obesity, high blood glucose, and high blood pressure, with the steepest increases occurring in low- and middle-income countries (Ghana, Jamaica, Seychelles) compared to the USA.

If you are of African descent, your risk for obesity, high blood sugar, and high blood pressure is actively increasing as you age, regardless of whether you live in a wealthy or developing country. The rate of increase is often faster in lower-income settings. This is not inevitable fate but a result of environmental and lifestyle shifts; proactive monitoring and lifestyle interventions are critical to mitigate this rising risk.

Endogenous GLP-1 and GIP hormones play a critical role in cardiovascular physiology, with GLP-1 promoting cardioprotection through anti-apoptotic signaling and improved glucose utilization, while GIP's role is complex and species-dependent.

Your body naturally produces hormones called GLP-1 and GIP that help protect your heart and blood vessels. GLP-1 improves blood flow, reduces inflammation, and helps your heart use energy efficiently during stress. GIP also plays a role in metabolism and heart health. Understanding these natural pathways helps explain why medications that mimic them are so effective for heart health.

Tirzepatide (0.144 mg/kg) significantly reduces voluntary alcohol consumption, prevents binge-like drinking, and suppresses relapse-like behaviors in rodents.

Tirzepatide, a dual GLP-1/GIP agonist, significantly reduces alcohol consumption and prevents relapse in rodent models by attenuating dopamine reward signaling. While preclinical, these findings suggest potential for treating Alcohol Use Disorder (AUD) and its metabolic complications.

Tirzepatide improves metabolic and inflammatory markers in alcohol-consuming rodents, including reducing body weight, white adipose tissue, hepatic triglycerides, and pro-inflammatory cytokines.

Tirzepatide improves metabolic health and reduces inflammation in alcohol-consuming rodents, potentially addressing comorbidities of AUD.

Intensive lifestyle interventions (ILI) targeting weight loss and physical activity in older adults (≥70 years) with type 2 diabetes and obesity are associated with increased odds of severe mobility disability compared to diabetes support and education (DSE).

For adults over 70 with type 2 diabetes, aggressive weight loss programs may increase the risk of severe mobility disability compared to standard diabetes education. Focus should shift towards preserving functional status and muscle mass rather than prioritizing significant weight reduction, as the loss of lean mass can outweigh the benefits of fat loss for mobility in this age group.

Higher BMI (Class 2+ obesity, ≥35 kg/m2) is consistently associated with increased odds of mobility, severe mobility, and IADL disability in older adults with type 2 diabetes, regardless of intervention group.

Maintaining a BMI below 35 kg/m2 is crucial for preserving mobility and independence in older adults with type 2 diabetes. While moderate weight loss might not be the primary goal for everyone, avoiding Class 2+ obesity (BMI ≥35) is strongly associated with lower risks of severe mobility and instrumental activities of daily living (IADL) disability.

Hospital normal diet meals in public North West province hospitals frequently fail to meet Recommended Dietary Intakes (RDIs) for key micronutrients, specifically folate, vitamin A, and vitamin B6, while often exceeding RDIs for energy, protein, carbohydrates, and fat.

If you are a patient in a public hospital, do not assume the standard 'normal diet' meets all your nutritional needs. The study shows these meals often lack essential vitamins (A, B6, Folate) even if they provide enough calories. Discuss your specific nutritional needs with a dietician or hospital manager, as portion control and menu planning are critical factors in preventing malnutrition and supporting recovery.

Pre-training bone characteristics (bone mineral content, bone area, shoulder/hip widths) do not meaningfully predict the magnitude of appendicular lean tissue mass hypertrophy following 10-12 weeks of resistance training in untrained adults.

Do not let your bone structure (shoulder width, hip width, or bone density) dictate your expectations for muscle growth. While larger bones are associated with more muscle at rest, they do not predict how much muscle you will gain from training. Focus on progressive overload and consistency; your skeletal frame is not a limiting factor for hypertrophy potential.

Pre-exhaustion resistance training (single-joint immediately before multi-joint) does not produce superior muscle hypertrophy or strength gains compared to traditional resistance training and may result in slightly lower hypertrophy due to reduced volume load.

If your goal is maximum muscle growth, stick to traditional resistance training (performing all sets of one exercise before moving to the next). While pre-exhaustion (doing a single-joint exercise right before a compound one) is time-efficient and viable for strength and endurance, it likely results in slightly less muscle growth because you lift less total weight (volume load) on the compound movements due to fatigue. Do not sacrifice volume load on compound lifts for the sake of pre-fatiguing muscles if hypertrophy is your primary goal.

Pre-training bone characteristics (bone mineral content, bone area, shoulder/hip width) do not significantly predict the magnitude of appendicular lean tissue mass gains following 10–12 weeks of resistance training in untrained adults.

Do not worry about your bone structure or frame size when starting resistance training. Whether you have wide shoulders or narrow hips, your potential for muscle growth is not determined by your skeleton. Focus on consistent training with progressive overload (increasing weight/reps over time) and adequate protein intake, as these are the drivers of hypertrophy, not your baseline bone density or width.

Isoenergetic pre-exercise meals with varying carbohydrate content (high vs. low) do not improve resistance training volume performance compared to a low-calorie placebo in resistance-trained individuals.

If you are eating a pre-workout meal, the specific amount of carbohydrates matters less than the total calories and protein, provided you are already eating a moderate amount of carbs throughout the day. You do not need to force-feed high-carb meals before lifting to maximize volume; a lower-carb, isoenergetic meal works just as well.

Tirzepatide (5, 10, and 15 mg weekly) improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis.

If you have moderate to severe fatty liver disease (MASH) with scarring (fibrosis), tirzepatide (5-15 mg weekly) can help resolve the liver inflammation and scarring in about 62% of patients at the highest dose, without making the scarring worse.

The adverse association between elevated BMI (>27 kg/m²) and mortality in HFrEF patients is significantly stronger in those with ischemic cardiomyopathy compared to non-ischemic cardiomyopathy.

If your heart failure is caused by coronary artery disease (ischemic), keeping your BMI under 27 is particularly important for your survival. In patients with non-ischemic heart failure, the link between higher BMI and death was not statistically significant in this study, suggesting that weight management strategies might need to be tailored to your specific heart condition.

Standardized multidisciplinary care and ERAS protocols reduce postoperative complications to ~1% and shorten hospital stays, improving overall safety and long-term outcomes.

Choosing a bariatric center that uses standardized protocols and multidisciplinary teams (surgeons, endocrinologists, psychologists) significantly lowers the risk of complications and shortens recovery time, leading to safer and more sustainable results.

Bariatric surgery (RYGB, Sleeve Gastrectomy) provides superior and more sustained weight loss (25-35%) and metabolic remission compared to pharmacotherapy, but carries higher surgical risks and potential for long-term complications.

Bariatric surgery (like gastric bypass or sleeve gastrectomy) is the most effective treatment for severe obesity, typically resulting in 25-35% weight loss. It offers significant improvements in diabetes and hypertension. However, it is invasive, carries surgical risks, and requires lifelong nutritional monitoring. It is generally recommended for those with BMI ≥ 40 or ≥ 35 with comorbidities who have not succeeded with other methods.

Leptin resistance is a common trait in obesity that impairs the feedback between fat mass and the hypothalamus, leading to dysregulated appetite and energy storage.

In obesity, the hormone leptin, which signals satiety, often stops working effectively (leptin resistance). This means the brain doesn't receive the 'stop eating' signal even when fat stores are high, contributing to continued overeating.

Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.

If you were recently diagnosed with high blood sugar, ask your doctor about a short course of intensive insulin therapy (2-3 weeks). This 'reset' can restore your body's ability to manage blood sugar on its own, potentially allowing you to avoid lifelong medication.

Tirzepatide exposure does not significantly increase or decrease the risk of adverse cardiovascular events (myocardial infarction, coronary artery disease, heart failure, stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) in participants with type 2 diabetes or obesity compared to control groups.

For patients with T2DM or obesity, current evidence from multiple randomized trials indicates that tirzepatide does not significantly increase or decrease the risk of major cardiovascular events (like heart attack or stroke) or specific renal adverse events (like kidney stones or UTIs) compared to other treatments or placebo. While long-term safety in high-risk groups requires more data, short-to-medium term use appears safe regarding these specific outcomes.